<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of transjugular intrahepatic portosystemic shunts (TIPS)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of transjugular intrahepatic portosystemic shunts (TIPS)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of transjugular intrahepatic portosystemic shunts (TIPS)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jasmohan S Bajaj, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Arun J Sanyal, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Felipe B Collares, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sanjiv Chopra, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen M Robson, MD, MBA, FACG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 18, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Portal hypertension often develops in patients with cirrhosis and may lead to complications such as variceal bleeding and ascites. Placement of a transjugular intrahepatic portosystemic shunt (TIPS) reduces elevated portal pressure by creating a low-resistance channel between the hepatic vein and an intrahepatic branch of the portal vein using angiographic techniques  (
         <a class="graphic graphic_figure graphicRef72311" href="/z/d/graphic/72311.html" rel="external">
          figure 1
         </a>
         ). The tract is kept patent by deployment of an expandable stent across it, thereby allowing blood to return to the systemic circulation. An advantage of TIPS is that it functions like a surgical side-to-side portacaval shunt that is created by a minimally invasive procedure without the risks associated with major surgery.
        </p>
        <p>
         An overview of TIPS including the indications, contraindications, and preprocedure testing will be discussed here.
        </p>
        <p>
         Postprocedure patient care, complications, and long-term monitoring for patients with TIPS are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1251.html" rel="external">
          "Transjugular intrahepatic portosystemic shunts: Postprocedure care and complications"
         </a>
         .)
        </p>
        <p>
         The clinical manifestations and diagnosis of portal hypertension in adults are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/90896.html" rel="external">
          "Portal hypertension in adults"
         </a>
         .)
        </p>
        <p>
         Management of patients with portal hypertension and acute variceal bleeding begins with hemodynamic resuscitation, airway protection, and antibiotic prophylaxis, and this is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1254.html" rel="external">
          "Overview of the management of patients with variceal bleeding"
         </a>
         .)
        </p>
        <p>
         Methods to achieve hemostasis in patients with variceal bleeding may focus on the bleeding site (eg, endoscopic variceal ligation, balloon tamponade) or may reduce the portal pressure directly (pharmacologic therapy, TIPS, surgically created shunts). In clinical practice, a combination of modalities is often used, and this is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1260.html" rel="external">
          "Methods to achieve hemostasis in patients with acute variceal hemorrhage"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          INDICATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H4274265862">
         <span class="h2">
          Bleeding related to portal hypertension
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h3">
          Esophageal varices
         </span>
        </p>
        <p class="headingAnchor" id="H3293316290">
         <span class="h4">
          Active bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         TIPS may be used for patients with actively bleeding esophageal varices who fail first-line methods of hemostasis or who have initial hemostasis but then rebleed within 120 hours of initial hemorrhage (see
         <a class="medical medical_review" href="/z/d/html/1260.html" rel="external">
          "Methods to achieve hemostasis in patients with acute variceal hemorrhage", section on 'Management if endoscopic therapy fails'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with active bleeding who fail initial therapy – TIPS is used as rescue therapy for patients with active variceal bleeding despite endoscopic and pharmacologic treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Multiple series have demonstrated efficacy of TIPS for active esophageal variceal bleeding despite endoscopic and pharmacologic treatment [
         <a href="#rid1">
          1-3
         </a>
         ]. Rates of immediate hemostasis after TIPS in most series range from 90 to 100 percent, while the mortality rates (measured at 30 days or 6 weeks) range from 10 to 75 percent [
         <a href="#rid1">
          1,3
         </a>
         ]. An illustrative report focused on 32 patients who were referred for TIPS after failing emergent endoscopic treatment [
         <a href="#rid4">
          4
         </a>
         ]. Patients were stabilized initially with balloon tamponade and TIPS was placed semi-emergently within 12 hours. Balloon tamponade was discontinued within 12 to 24 hours after TIPS placement. The six-week survival was 60 percent in this patient cohort whose expected survival rate, based upon historical controls, was approximately 10 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with active bleeding who had achieved initial hemostasis – Emerging data suggest that elective TIPS placement within 72 hours of initial endoscopic hemostasis (early TIPS) results in better outcomes for patients who are high risk for rebleeding (eg, Child-Pugh class C, hepatic venous pressure gradient of 20 mmHg) [
         <a href="#rid5">
          5-10
         </a>
         ]. In a trial including 132 patients with cirrhosis with variceal bleeding who were treated with pharmacologic and endoscopic therapy resulting in hemostasis, patients with early TIPS placement had higher rates of transplant-free survival compared with patients without TIPS (79 versus 64 percent at two years; hazard ratio for death or liver transplant 0.50, 95% CI 0.25-0.98), while the rate of hepatic encephalopathy was not significantly different between groups [
         <a href="#rid9">
          9
         </a>
         ]. While these results show promise, further trials are needed to verify the mortality benefit of early TIPS before it is routinely placed in patients with decompensated cirrhosis and high mortality risk. (See
         <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">
          "Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Child-Pugh classification'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H701373247">
         <span class="h4">
          Preventing recurrent bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Options for preventing recurrent variceal bleeding (ie, &gt;120 hours after initial hemorrhage) after successful treatment of variceal hemorrhage include pharmacologic therapy with a nonselective beta blocker and/or endoscopic variceal ligation with the goal of obliterating esophageal varices. However, some patients develop recurrent variceal hemorrhage despite these preventive strategies. The use and efficacy of TIPS as a long-term strategy for hemostasis for patients with a history of bleeding esophageal varices is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1252.html" rel="external">
          "Prevention of recurrent bleeding from esophageal varices in patients with cirrhosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Gastric varices
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial treatment for bleeding fundic gastric varices is pharmacologic (eg,
         <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">
          octreotide
         </a>
         ) with balloon tamponade, which is a temporary measure. When initial therapy fails to achieve hemostasis, subsequent options include TIPS or endoscopic or surgical interventions. The approach to patients with bleeding gastric varices is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1260.html" rel="external">
          "Methods to achieve hemostasis in patients with acute variceal hemorrhage", section on 'Management of gastric varices'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4006152912">
         <span class="h3">
          Ectopic varices
         </span>
         <span class="headingEndMark">
          —
         </span>
         Varices may develop at sites other than the esophagus and/or stomach, and these are typically identified when patients develop bleeding. Examples of ectopic varices include duodenal, rectal, or peristomal varices (ie, varices that develop in patients with a stoma [typically following colectomy]). The use and efficacy of TIPS for achieving hemostasis in patients with bleeding ectopic varices is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1260.html" rel="external">
          "Methods to achieve hemostasis in patients with acute variceal hemorrhage", section on 'Management of ectopic varices'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H510570482">
         <span class="h3">
          Portal hypertensive gastropathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         TIPS is a treatment option for patients with bleeding from portal hypertensive gastropathy who fail to respond to pharmacologic therapy (eg, nonselective beta blocker), and this is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2645.html" rel="external">
          "Portal hypertensive gastropathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2286233358">
         <span class="h2">
          Refractory ascites
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of TIPS for the management of refractory ascites is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1258.html" rel="external">
          "Ascites in adults with cirrhosis: Diuretic-resistant ascites"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2720696027">
         <span class="h2">
          Other uses
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other conditions that have been managed with TIPS include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Budd Chiari Syndrome (see
         <a class="medical medical_review" href="/z/d/html/93786.html" rel="external">
          "Budd-Chiari syndrome: Management", section on 'Transjugular intrahepatic portosystemic shunt'
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatic hydrothorax (see
         <a class="medical medical_review" href="/z/d/html/1242.html" rel="external">
          "Hepatic hydrothorax", section on 'Transjugular intrahepatic portosystemic shunt'
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Investigational uses – Small case series describe the use of TIPS for patients with hepatic sinusoidal obstruction syndrome (veno-occlusive disease), which is complication of bone marrow transplantation [
         <a href="#rid11">
          11-13
         </a>
         ]. While some patients had improvement in ascites after TIPS placement, long-term survival was uncommon.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The pathophysiology of sinusoidal obstruction syndrome is related to increased sinusoidal pressures from occlusion of microscopic hepatic venules and central veins in the hepatic lobules, and this is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/129806.html" rel="external">
          "Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         TIPS has been studied for treating patients with hepatorenal syndrome. (See
         <a class="medical medical_review" href="/z/d/html/2308.html" rel="external">
          "Hepatorenal syndrome", section on 'Transjugular intrahepatic portosystemic shunt'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H984741252">
         <span class="h1">
          CONTRAINDICATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1138918985">
         <span class="h2">
          Absolute contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Absolute contraindications to TIPS placement include [
         <a href="#rid14">
          14
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Congestive heart failure – Cardiac decompensation and/or failure is a complication of TIPS and results from a large volume blood shift from the splanchnic to the systemic circulation, increasing venous return to the heart, cardiac output, and right heart pressures. (See
         <a class="medical medical_review" href="/z/d/html/1251.html" rel="external">
          "Transjugular intrahepatic portosystemic shunts: Postprocedure care and complications", section on 'Cardiac failure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe tricuspid regurgitation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe pulmonary hypertension (mean pulmonary pressure &gt;45 mmHg).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polycystic liver disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Active systemic infection or sepsis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unrelieved biliary obstruction.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3136129005">
         <span class="h2">
          Relative contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Relative contraindications to TIPS include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatic tumors, especially if centrally located.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obstruction of all hepatic veins.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatic encephalopathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Portal vein thrombosis (see
         <a class="medical medical_review" href="/z/d/html/88014.html" rel="external">
          "Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management"
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombocytopenia (&lt;20,000/microL).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate pulmonary hypertension (see
         <a class="medical medical_review" href="/z/d/html/8262.html" rel="external">
          "Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults", section on 'Classification and definitions'
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         In addition, while TIPS is indicated for treating active variceal bleeding, resuscitation measures and pharmacologic therapy are initiated in an effort to stabilize patients with active bleeding prior to transporting them to interventional radiology for the procedure. (See
         <a class="medical medical_review" href="/z/d/html/1254.html" rel="external">
          "Overview of the management of patients with variceal bleeding", section on 'Initial measures'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4118230657">
         <span class="h1">
          PRE-TIPS EVALUATION AND PLANNING
         </span>
        </p>
        <p class="headingAnchor" id="H1756860614">
         <span class="h2">
          Preprocedure testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to TIPS placement, we typically obtain the following tests; however, there is no consensus on preprocedure testing in this setting:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laboratory testing:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complete blood count
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Total bilirubin
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         International normalized ratio
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum creatinine
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Model for End-stage Liver disease (MELD) score – The MELD score is calculated based on the patient's creatinine, bilirubin, and international normalized ratio (INR), and has proven to be superior to the Child–Pugh score for predicting post-TIPS mortality (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.mayoclinic.org%2Fmedical-professionals%2Fcalculators%2Fmeld-model%2Fitt-20434705&amp;token=3pDetqxXfy35JzfJAhU2tqIVKNBeLcPRuu0UDmkjMGwjdo68kfahLv6%2BZQ3WYVWAVk2CFU5pjSEbH7YljsMChVffFdn0DDYJqwA5pUi25SRP0wVJMZIdJmP5RdaJrgnV&amp;TOPIC_ID=1265" target="_blank">
          MELD score
         </a>
         ). Patients with a MELD score &gt;18 have a higher risk of mortality at three months after TIPS than those with a MELD score of ≤18 [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Imaging – Liver imaging is performed to assess for patency of the portal and hepatic veins, spleen size, ascites, and presence and extent of portosystemic collaterals [
         <a href="#rid16">
          16
         </a>
         ]. Contrast enhanced imaging (ie, computed tomography or magnetic resonance imaging) is typically performed prior to TIPS placement; however, a noncontrast abdominal ultrasound with Doppler study is a reasonable alternative for some patients (ie, those with renal impairment or active variceal bleeding) [
         <a href="#rid17">
          17
         </a>
         ]. Patient evaluation prior to administration of intravenous contrast agents is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/113083.html" rel="external">
          "Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">
          "Patient evaluation before gadolinium contrast administration for magnetic resonance imaging"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A chest radiograph is obtained to evaluate for abnormalities such as fluid overload and cardiomegaly.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Additional testing – A cardiac evaluation should be performed prior to TIPS placement in patients with signs, symptoms, or a history of heart failure, tricuspid regurgitation, cardiomyopathy, or pulmonary hypertension. The evaluation often includes an echocardiogram and specialty consultation (eg, cardiology, pulmonary). (See
         <a class="medical medical_review" href="/z/d/html/1251.html" rel="external">
          "Transjugular intrahepatic portosystemic shunts: Postprocedure care and complications", section on 'Cardiac failure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The evaluation of patients with suspected heart failure or pulmonary hypertension is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">
          "Heart failure: Clinical manifestations and diagnosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1303116885">
         <span class="h2">
          Preprocedure preparation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibiotic prophylaxis is routinely given to patients at the time of TIPS insertion. An antibiotic with broad coverage against Gram-negative bacteria is selected, and we typically use
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         1 g intravenously once [
         <a href="#rid18">
          18,19
         </a>
         ]. Transient bacteremia during the creation of the TIPS shunt is common (up to 35 percent of patients), as enteric bacteria within the static portal system can enter the systemic circulation [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1287012400">
         <span class="h1">
          PROCEDURE
         </span>
        </p>
        <p class="headingAnchor" id="H1738124497">
         <span class="h2">
          Positioning and anesthesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         For TIPS placement, the patient typically lies in a supine position, and either general anesthesia or monitored anesthesia care (MAC) is used. Anesthesia for TIPS and other interventional radiology procedures is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/102831.html" rel="external">
          "Considerations for non-operating room anesthesia (NORA)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/91242.html" rel="external">
          "Anesthesia for the patient with liver disease", section on 'Anesthesia for transhepatic portosystemic shunt'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2211905223">
         <span class="h2">
          Technique
         </span>
         <span class="headingEndMark">
          —
         </span>
         The general steps for performing TIPS placement include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obtain vascular access through the right internal jugular vein.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Advance the catheter into the right or middle hepatic veins and perform hepatic venogram.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Advance the TIPS sheath and cannula into the proximal hepatic vein and perform carbon dioxide (CO
         <sub>
          2
         </sub>
         ) portovenogram to localize and target the intrahepatic segment of the portal vein.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use the TIPS needle and catheter to obtain access into the portal venous system.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perform portal venogram  (
         <a class="graphic graphic_diagnosticimage graphicRef130103" href="/z/d/graphic/130103.html" rel="external">
          image 1
         </a>
         ) and obtain direct portal venous pressures to calculate pre-TIPS portosystemic venous pressure gradient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perform balloon dilation of the intrahepatic tract between the hepatic and portal veins.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Create the shunt by deploying a covered stent  (
         <a class="graphic graphic_diagnosticimage graphicRef130104" href="/z/d/graphic/130104.html" rel="external">
          image 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obtain post-TIPS portosystemic gradient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If esophageal or gastric varices require intervention, perform embolization of varices using coils, plugs, and/or sclerosing agents  (
         <a class="graphic graphic_diagnosticimage graphicRef130106" href="/z/d/graphic/130106.html" rel="external">
          image 3
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/1260.html" rel="external">
          "Methods to achieve hemostasis in patients with acute variceal hemorrhage", section on 'Alternative treatments'
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4240029107">
         <span class="h2">
          Intraprocedure complications
         </span>
        </p>
        <p class="headingAnchor" id="H1455762662">
         <span class="h3">
          Anesthesia-related issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         TIPS is typically performed with monitored anesthesia care or general anesthesia, and choice of anesthetic technique and effect of anesthesia on the liver are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/91242.html" rel="external">
          "Anesthesia for the patient with liver disease", section on 'Anesthesia for transhepatic portosystemic shunt'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3568899143">
         <span class="h3">
          Cardiac arrhythmias
         </span>
         <span class="headingEndMark">
          —
         </span>
         As the TIPS catheter is passed through the heart before accessing the hepatic vein, cardiac arrhythmias may develop. This is most likely to occur if the catheter bulges within the right atrium and rubs against the atrial wall or prolapses into the right ventricle; however, use of a relatively stiff introducer for venous access may help maintain a straight catheter [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Although premature atrial complex (also referred to as premature atrial beat, premature supraventricular complex, or premature supraventricular beat) have little clinical significance, more serious arrhythmias, such as atrial fibrillation, conduction defects (nodal or infranodal), and ventricular tachycardia, can occur [
         <a href="#rid22">
          22
         </a>
         ]. Potential contributing factors that may lead to cardiac arrhythmias (eg, electrolyte and acid-base abnormalities) should be identified and corrected, prior to the procedure; this is discussed separately. (See
         <a class="local">
          'Pre-TIPS evaluation and planning'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H652423440">
         <span class="h3">
          Liver capsule puncture
         </span>
         <span class="headingEndMark">
          —
         </span>
         A potentially serious complication of creating an intrahepatic tract is traversal of the liver capsule during attempts to enter the portal vein. The reported incidence of capsule traversal is approximately 33 percent [
         <a href="#rid21">
          21
         </a>
         ]; however, the development of clinically significant hemoperitoneum (eg, hemodynamic instability) is uncommon [
         <a href="#rid23">
          23
         </a>
         ]. This complication is most likely to occur in two settings: when the liver is small, hard, and displaced upward by ascites, thereby making the angle necessary to enter the portal vein from the hepatic vein very acute; or when the portal vein is thrombosed and replaced by collaterals. Management of liver capsule rupture and/or laceration includes balloon tamponade and coil embolization of the bleeding vessel [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         To minimize the risk of puncturing the liver capsule, portal vein patency is routinely assessed with imaging (eg, ultrasound with doppler imaging, portal venography) prior to TIPS insertion [
         <a href="#rid25">
          25
         </a>
         ]. In addition, the interventional radiologist may remove ascites prior to the procedure because this may help to stabilize the liver during transparenchymal puncture. (See
         <a class="local">
          'Pre-TIPS evaluation and planning'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1052960421">
         <span class="h3">
          Other complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other complications of TIPS insertion include [
         <a href="#rid24">
          24
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Portal vein rupture – A rare but potentially fatal complication of TIPS insertion is extrahepatic puncture of the portal vein with severe bleeding after attempts to dilate the site of portal vein puncture [
         <a href="#rid21">
          21
         </a>
         ]. The portal vein should ideally be accessed in an intrahepatic location to avoid hemorrhagic complications; however, there are reports of achieving hemostasis by placing a covered TIPS across the site of injury [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Injury to the biliary tree – The creation of biliary fistula during TIPS insertion is uncommon [
         <a href="#rid21">
          21
         </a>
         ]. While isolated injury to the bile ducts may be well tolerated, biliary or vascular fistulas may lead to hemobilia, cholangitis, and infection [
         <a href="#rid27">
          27
         </a>
         ]. In addition, communication between TIPS and the biliary system has been associated with stenosis and shunt occlusion  (
         <a class="graphic graphic_picture graphicRef77747" href="/z/d/graphic/77747.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid28">
          28,29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1323623203">
         <span class="h1">
          POSTPROCEDURE CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postprocedure care and long-term monitoring for patients with TIPS are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1251.html" rel="external">
          "Transjugular intrahepatic portosystemic shunts: Postprocedure care and complications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1028444381">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114134.html" rel="external">
          "Society guideline links: Gastrointestinal bleeding in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114698.html" rel="external">
          "Society guideline links: Portal hypertension and ascites"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H342758375">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/4581.html" rel="external">
          "Patient education: Esophageal varices (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Background
         </strong>
         – Portal hypertension often develops in patients with cirrhosis and may lead to complications such as variceal bleeding and ascites. Placement of a TIPS reduces elevated portal pressure by creating a low-resistance channel between the hepatic vein and an intrahepatic branch of the portal vein  (
         <a class="graphic graphic_figure graphicRef72311" href="/z/d/graphic/72311.html" rel="external">
          figure 1
         </a>
         ). The tract is kept patent by deployment of an expandable stent across it, thereby allowing blood to return to the systemic circulation. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with actively bleeding esophageal varices who either fail first-line methods of hemostasis or who have initial hemostasis but then rebleed within five days, TIPS is an option for achieving both short- and long-term hemostasis. (See
         <a class="medical medical_review" href="/z/d/html/1260.html" rel="external">
          "Methods to achieve hemostasis in patients with acute variceal hemorrhage"
         </a>
         and
         <a class="local">
          'Esophageal varices'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who develop recurrent variceal bleeding despite use of a preventive strategy (nonselective beta blocker and/or endoscopic variceal ligation), TIPS is an option for achieving long-term hemostasis, and the efficacy of TIPS in this setting is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1252.html" rel="external">
          "Prevention of recurrent bleeding from esophageal varices in patients with cirrhosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The use of TIPS for the management of refractory ascites is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1258.html" rel="external">
          "Ascites in adults with cirrhosis: Diuretic-resistant ascites"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications
         </strong>
         – Absolute contraindications to TIPS placement include (see
         <a class="local">
          'Absolute contraindications'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Congestive heart failure
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe tricuspid regurgitation
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe pulmonary hypertension (mean pulmonary pressure &gt;45 mmHg)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Polycystic liver disease
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Active systemic infection or sepsis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Unrelieved biliary obstruction
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pre-TIPS evaluation and planning
         </strong>
         – Prior to placement of TIPS, we typically obtain the following studies (see
         <a class="local">
          'Pre-TIPS evaluation and planning'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Laboratory testing – Complete blood count, total bilirubin, international normalized ratio, and serum creatinine. The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.mayoclinic.org%2Fmedical-professionals%2Fcalculators%2Fmeld-model%2Fitt-20434705&amp;token=3pDetqxXfy35JzfJAhU2tqIVKNBeLcPRuu0UDmkjMGwjdo68kfahLv6%2BZQ3WYVWAVk2CFU5pjSEbH7YljsMChVffFdn0DDYJqwA5pUi25SRP0wVJMZIdJmP5RdaJrgnV&amp;TOPIC_ID=1265" target="_blank">
          MELD score
         </a>
         is calculated.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Imaging – Liver imaging (contrast-enhanced liver imaging [ie, computed tomography or magnetic resonance imaging] or noncontrast abdominal ultrasound with Doppler study) and chest radiograph.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Additional evaluation is performed for selected patients (eg, echocardiography and cardiology consultation for patients with signs or symptoms of heart failure).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postprocedure care
         </strong>
         – Postprocedure care and adverse events related to TIPS are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1251.html" rel="external">
          "Transjugular intrahepatic portosystemic shunts: Postprocedure care and complications"
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Vangeli M, Patch D, Burroughs AK. Salvage tips for uncontrolled variceal bleeding. J Hepatol 2002; 37:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azoulay D, Castaing D, Majno P, et al. Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol 2001; 35:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu Y, Wang X, Xi X, et al. Emergency Transjugular Intrahepatic Portosystemic Shunt: an Effective and Safe Treatment for Uncontrolled Variceal Bleeding. J Gastrointest Surg 2019; 23:2193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanyal AJ, Freedman AM, Luketic VA, et al. Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology 1996; 111:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004; 40:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Pagán JC, Di Pascoli M, Caca K, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol 2013; 58:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Njei B, McCarty TR, Laine L. Early transjugular intrahepatic portosystemic shunt in US patients hospitalized with acute esophageal variceal bleeding. J Gastroenterol Hepatol 2017; 32:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conejo I, Guardascione MA, Tandon P, et al. Multicenter External Validation of Risk Stratification Criteria for Patients With Variceal Bleeding. Clin Gastroenterol Hepatol 2018; 16:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lv Y, Yang Z, Liu L, et al. Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial. Lancet Gastroenterol Hepatol 2019; 4:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Afdhal NH, Curry MP. Early TIPS to improve survival in acute variceal bleeding. N Engl J Med 2010; 362:2421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fried MW, Connaghan DG, Sharma S, et al. Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology 1996; 24:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azoulay D, Castaing D, Lemoine A, et al. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant 2000; 25:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Annaloro C, Robbiolo L, Pozzoli E, et al. Four-year survival after trans-jugular intrahepatic porto-systemic shunt for veno-occlusive disease following autologous bone marrow transplantation. Leuk Lymphoma 2004; 45:1485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dariushnia SR, Haskal ZJ, Midia M, et al. Quality Improvement Guidelines for Transjugular Intrahepatic Portosystemic Shunts. J Vasc Interv Radiol 2016; 27:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salerno F, Merli M, Cazzaniga M, et al. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol 2002; 36:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tripathi D, Stanley AJ, Hayes PC, et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut 2020; 69:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krajina A, Hulek P, Fejfar T, Valek V. Quality improvement guidelines for Transjugular Intrahepatic Portosystemic Shunt (TIPS). Cardiovasc Intervent Radiol 2012; 35:1295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venkatesan AM, Kundu S, Sacks D, et al. Practice guidelines for adult antibiotic prophylaxis during vascular and interventional radiology procedures. Written by the Standards of Practice Committee for the Society of Interventional Radiology and Endorsed by the Cardiovascular Interventional Radiological Society of Europe and Canadian Interventional Radiology Association [corrected]. J Vasc Interv Radiol 2010; 21:1611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chehab MA, Thakor AS, Tulin-Silver S, et al. Adult and Pediatric Antibiotic Prophylaxis during Vascular and IR Procedures: A Society of Interventional Radiology Practice Parameter Update Endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology. J Vasc Interv Radiol 2018; 29:1483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeSimone JA, Beavis KG, Eschelman DJ, Henning KJ. Sustained bacteremia associated with transjugular intrahepatic portosystemic shunt (TIPS). Clin Infect Dis 2000; 30:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedman AM, Sanyal AJ, Tisnado J, et al. Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review. Radiographics 1993; 13:1185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pidlich J, Peck-Radosavljevic M, Kranz A, et al. Transjugular intrahepatic portosystemic shunt and cardiac arrhythmias. J Clin Gastroenterol 1998; 26:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaBerge JM, Ring EJ, Gordon RL, et al. Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprosthesis: results in 100 patients. Radiology 1993; 187:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaba RC, Khiatani VL, Knuttinen MG, et al. Comprehensive review of TIPS technical complications and how to avoid them. AJR Am J Roentgenol 2011; 196:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Downing TM, Khan SN, Zvavanjanja RC, et al. Portal Venous Interventions: How to Recognize, Avoid, or Get Out of Trouble in Transjugular Intrahepatic Portosystemic Shunt (TIPS), Balloon Occlusion Sclerosis (ie, BRTO), and Portal Vein Embolization (PVE). Tech Vasc Interv Radiol 2018; 21:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krajina A, Hulek P, Ferko A, Nozicka J. Extrahepatic portal venous laceration in TIPS treated with stent graft placement. Hepatogastroenterology 1997; 44:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanyal AJ, Freedman AM, Luketic VA, et al. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997; 112:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saxon RR, Mendel-Hartvig J, Corless CL, et al. Bile duct injury as a major cause of stenosis and occlusion in transjugular intrahepatic portosystemic shunts: comparative histopathologic analysis in humans and swine. J Vasc Interv Radiol 1996; 7:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaBerge JM, Ferrell LD, Ring EJ, Gordon RL. Histopathologic study of stenotic and occluded transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 1993; 4:779.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1265 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12399244" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Salvage tips for uncontrolled variceal bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11690704" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30790218" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Emergency Transjugular Intrahepatic Portosystemic Shunt: an Effective and Safe Treatment for Uncontrolled Variceal Bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8698192" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15382120" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22940408" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27624167" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Early transjugular intrahepatic portosystemic shunt in US patients hospitalized with acute esophageal variceal bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28501536" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Multicenter External Validation of Risk Stratification Criteria for Patients With Variceal Bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31153882" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20573931" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Early TIPS to improve survival in acute variceal bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8781329" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10800068" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15359654" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Four-year survival after trans-jugular intrahepatic porto-systemic shunt for veno-occlusive disease following autologous bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26614596" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Quality Improvement Guidelines for Transjugular Intrahepatic Portosystemic Shunts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11943420" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32114503" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23070105" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Quality improvement guidelines for Transjugular Intrahepatic Portosystemic Shunt (TIPS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21029949" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Practice guidelines for adult antibiotic prophylaxis during vascular and interventional radiology procedures. Written by the Standards of Practice Committee for the Society of Interventional Radiology and Endorsed by the Cardiovascular Interventional Radiological Society of Europe and Canadian Interventional Radiology Association [corrected].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30274857" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Adult and Pediatric Antibiotic Prophylaxis during Vascular and IR Procedures: A Society of Interventional Radiology Practice Parameter Update Endorsed by the Cardiovascular and Interventional Radiological Society of Europe and the Canadian Association for Interventional Radiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10671346" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Sustained bacteremia associated with transjugular intrahepatic portosystemic shunt (TIPS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8290720" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9492862" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Transjugular intrahepatic portosystemic shunt and cardiac arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8475283" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprosthesis: results in 100 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21343513" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Comprehensive review of TIPS technical complications and how to avoid them.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30545506" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Portal Venous Interventions: How to Recognize, Avoid, or Get Out of Trouble in Transjugular Intrahepatic Portosystemic Shunt (TIPS), Balloon Occlusion Sclerosis (ie, BRTO), and Portal Vein Embolization (PVE).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9222668" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Extrahepatic portal venous laceration in TIPS treated with stent graft placement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9041251" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8855524" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Bile duct injury as a major cause of stenosis and occlusion in transjugular intrahepatic portosystemic shunts: comparative histopathologic analysis in humans and swine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8281000" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Histopathologic study of stenotic and occluded transjugular intrahepatic portosystemic shunts.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
